The heart rate of the baby is critical for guiding the stabilisation or resuscitation process; however, current monitoring methods do not always provide an early enough or sometimes an accurate enough heart rate which can lead to inappropriate clinical interventions (Voogdt). Adherence to guidelines is sub-optimal (Mann, Cusack) which impacts on babies’ welfare, their families, and healthcare resources.
Receiving the right information at the right time is essential for adherence to guidelines, yet ‘guideline errors’ exist and there is significant variation from gold-standard protocols such as the Newborn Life Support Guidelines in the UK (Cusack, Duran).
Delayed resuscitation can have significant consequences. In 2017 there were 1,267 neonatal deaths in the UK, 68% of them between birth and 7 days, 119 of them were from cardio-respiratory causes (MBRRACE 2019).
Access to timely accurate heart rate information remains an opportunity that SurePulse VS can help address.
“The SurePulse device has potential to be a significant advancement in the way neonatal patients are monitored in a variety of post-delivery circumstances”
Frontiers in Pediatrics
Frontiers
SurePulse Medical Limited
Medicity, D6 Thane Road,
Nottingham,
NG90 6BH
United Kingdom